Designed by
patients for patients

Clarify Medical was founded by a psoriasis patient, Martyn Gross, who had excellent results with UVB therapy but found it very difficult to receive in-office treatment three times a week. His concept of a mobile, easy-to-use home UVB system, linked with the patient's physician, inspired years of research and development with hundreds of psoriasis and vitiligo patients and their physicians. Patients designed the integrated technology and service solution we offer today.

The Clarify Management Team

Our team of physicians, engineers, software experts, patient advisors and scientists are dedicated to creating new products and services that support patients and the clinicians who care for them.

Clarify. Life in a New Light.

George Mahaffey

President & CEO

Mr. Mahaffey is the President and CEO of Clarify Medical, and has over 30 years of pharmaceutical and biotechnology industry experience. In March 2011 he was named President and CEO of Lithera, Inc., later renamed Neothetics, a clinical stage special pharmaceutical aesthetics company.  While there he successfully completed an IPO in November 2014.  He previously served as CEO of Peplin, Inc. after the dermatology company was acquired by LEO Pharma A/S in 2009, where he played an instrumental role in the transaction. Prior to the acquisition, he served as Peplin’s Chief Commercial Officer and VP, Sales and Marketing. Mr. Mahaffey also served as Sr. VP, Sales and Marketing for Cotherix, Inc. where he led the corporate commercialization and successful launch of Ventavis® (iloprost), an orphan drug to treat Pulmonary Arterial Hypertension. He was heavily involved in the acquisition of CoTherix by Actelion Ltd. in 2007. Prior to CoTherix, Mr. Mahaffey worked at Scios, Inc. (acquired by Johnson & Johnson in 2003) where he led the launch of Natrecor® (nesiritide) to treat acutely decompensated congestive heart failure. Mr. Mahaffey also worked in various marketing functions at Neurex, Inc. (acquired by Elan Corp. in 1998). He began his pharmaceutical career at DuPont Pharmaceuticals where he held various sales and marketing positions. Mr. Mahaffey has a Chemical Engineering degree from the University of Delaware and an MBA from the University of South Florida.

Don Canal

Don Canal has over 25 years of experience in the medical device industry serving in senior management positions in Design & Development, and Quality and Regulatory Affairs with startup companies such as CardioNet, Tandem Diabetes Care and most recently, Ivera Medical which was sold to 3M in March 2015. He has also served as VP GM for leading contract medical device design, research and development and manufacturing services.

Wael Ahwal

Wael has 16 years of experience in the medical device and the diagnostic industry, holding senior positions in Design & Development, Software Validation and Verification, and Quality. Wael started his career at L3 Communication, moved to Gen-Probe, where he joined the Software Validation and Verification team as a lead. Most recently he served as Director of Quality Systems at Sotera Wireless.

Teddy Fulham

Teddy has been working in the medical device and health information technology sectors for the past ten years. Prior to joining Clarify in 2016, Teddy was responsible for Strategy and Product Management at Sotera Wireless, an early pioneer in the wearable continuous vital sign monitoring space, where he launched its next-generation software platform. Before Sotera, Teddy was a Market Manager for Pyxis Medication Management Technologies, which was acquired as part of Becton Dickinson’s acquisition of CareFusion in 2015. In this role, he established Pyxis’ competitive intelligence program and was a key member of the team which established its healthcare economics and outcomes research program. Earlier in his career, he graduated from CareFusion’s three-year Finance Leadership Development Program, in which he held roles in corporate finance, accounting and business unit financial planning & analysis. Teddy graduated magna cum laude with a B.S. in Finance (Honors Program) from the University of San Diego, where he also played Division 1AA football and received the USD Presidential Scholar Athlete Award.

Andre Gamelin

Andre Gamelin is a medical technology innovator with extensive experience leading the development of electro-mechanical and electro-optical products.  Andre joined Clarify Medical at the beginning, where he studied the needs of patients and physicians, and architected a technology driven system to provide precision home phototherapy to patients with chronic skin conditions. Andre is a named inventor on the core Clarify patents protecting the smart-phone connected system and the precision lighting engine.

Prior to leading product development at Clarify Medical, Andre held leadership positions at Becton-Dickinson (CareFusion) developing critical infusion pumps, at Masimo Corporation developing non-invasive blood gas sensors using LED technology, and at Inovio Biomedical developing electroporation devices for cancer & DNA therapies. Andre co-founded Allegrotek, a product development and contract manufacturing company and also developed a real-time blood gas analyzer at Medtronic (Puritan-Bennett). Andre holds a BS degree in electrical engineering from UCSD.

The Clarify Board of Directors

David F. Hale

Mr. Hale serves as Chairman of the Board of Clarify Medical, Inc. He is Chairman and CEO of Hale Biopharma Ventures, LLC, a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic and medical device companies. He was involved in the formation and development of SkinMedica, an aesthetic skincare company, and served as Executive Chairman and Chairman from 2001 through that company’s sale to Allergan for $315 million.

Mr. Hale served as Chairman of Santarus, Inc. prior to its sale to Salix Pharmaceuticals in 2014, Micromet prior to its sale to Amgen in 2012 for $1.2 billion, Somaxon Pharmaceuticals prior to its sale to Permix in 2013, and Crisi Medical Systems prior to its sale to Becton Dickinson & Co. in 2015.    

Mr. Hale is a serial entrepreneur who has been involved in the formation and/or development of many other life sciences companies. In addition to the companies above, these include Hybritech, Viagene, Gensia Sicor, CancerVax, Neurelis, MDRejuvena, Dermata, Adgica Health, Oncternal, Agility Clinical, Biocept, Neurana and Colorescience, Inc. He serves on the board of two public companies, Conatus and BIOCEPT.

Raymond Huggenberger

Mr. Huggenberger is a Director of Inogen, Inc. and served as its CEO from 2008-2017 and as its President from 2008-2016. Mr. Huggenberger led the company through a period of rapid revenue growth through direct-to-patient marketing, during which its share price increased.

He formerly served as President and COO and Group President of European Operations of Sunrise Medical Inc. He also previously served as President of Sunrise Medical Germany and as its Vice President of Marketing. Mr. Huggenberger also serves on the Board of Directors of Wellfount Corporation, Tactile Medical Systems and Sommetrics Inc. and is a member of the Technical Advisory Board of Arboretum Ventures LLP.

Mr. Huggenberger has over 20 years of deep experience in outpatient health care products and services, and in direct to patient and international sales and marketing.

George Mahaffey

Mr. Mahaffey is the President and CEO of Clarify Medical, and has over 30 years of pharmaceutical and biotechnology industry experience. In March 2011 he was named President and CEO of Lithera, Inc., later renamed Neothetics, a clinical stage special pharmaceutical aesthetics company.  While there he successfully completed an IPO in November 2014.  He previously served as CEO of Peplin, Inc. after the dermatology company was acquired by LEO Pharma A/S in 2009, where he played an instrumental role in the transaction. Prior to the acquisition, he served as Peplin’s Chief Commercial Officer and VP, Sales and Marketing. Mr. Mahaffey also served as Sr. VP, Sales and Marketing for Cotherix, Inc. where he led the corporate commercialization and successful launch of Ventavis® (iloprost), an orphan drug to treat Pulmonary Arterial Hypertension. He was heavily involved in the acquisition of CoTherix by Actelion Ltd. in 2007. Prior to CoTherix, Mr. Mahaffey worked at Scios, Inc. (acquired by Johnson & Johnson in 2003) where he led the launch of Natrecor® (nesiritide) to treat acutely decompensated congestive heart failure. Mr. Mahaffey also worked in various marketing functions at Neurex, Inc. (acquired by Elan Corp. in 1998). He began his pharmaceutical career at DuPont Pharmaceuticals where he held various sales and marketing positions. Mr. Mahaffey has a Chemical Engineering degree from the University of Delaware and an MBA from the University of South Florida.

Blog

HOME PHOTOTHERAPY

What is Phototherapy? Phototherapy – Ultraviolet (UV) Light Therapy Light therapy, also known as phototherapy, is the use of ultraviolet (UV) light for its healing effects. Phototherapy has been used worldwide for nearly a century to treat chronic skin conditions such as psoriasis, vitiligo and severe eczema. While many treatments decrease the overall immune system,….

Patient Spotlight: Q&A with Mom

by Phototherapy, Vitiligo

When it comes to managing chronic skin conditions, all successes are worth celebrating – small and large. We wanted to take this time to recognize one of our patients who has seen incredible results using the Clarify System in a short period of time. Since this patient is only 8 years old, we asked his….

News & Media

Contact Us.
We’re here to help.

Clarify Medical
10505 Sorrento Valley Rd. Suite 450
San Diego, CA 92121

Corporate / General Support: +1 (877) 520-5697
Sales Support: +1 (877) 738-6041
Fax: +1 (844) 562-6896

info@clarifymed.com

We are committed to providing innovative technology and support services for people with chronic skin conditions. We welcome your feedback and invite your questions.

Contact Form Inquire Reason: